Identification of three unexpected new psychoactive substances at an Australian drug checking service

Jess L. Algar, Douglas J. Lawes, Adam J. Carroll, David Caldicott, Malcolm D. McLeod*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)

    Abstract

    Drug checking is a harm reduction measure that provides people with the opportunity to confirm the identity and purity of substances before consumption. The CanTEST Health and Drug Checking Service is Australia's first fixed-site drug checking service, where clients can learn about the contents of the samples they provide while receiving tailored harm reduction and health advice. Three samples were recently presented to the service with the expectation of 4-fluoromethylphenidate (4F-MPH) 1, methoxetamine (MXE) 2 and 3-methylmethcathinone (3-MMC) 3. The identity of all three samples did not meet these expectations and remained unknown on-site, as no high confidence identifications were obtained. However, further analysis by nuclear magnetic resonance spectroscopy, high resolution gas chromatography-electron ionisation-mass spectrometry and liquid chromatography-electrospray ionisation-mass spectrometry at the nearby Australian National University allowed for the structure elucidation of the three samples as 4-fluoro-alpha-pyrrolidinoisohexanophenone (4F-alpha-PiHP) 4, 1-(4-fluorobenzyl)-4-methylpiperazine (4F-MBZP) 5 and N-propyl-1,2-diphenylethylamine (propylphenidine) 6, respectively. Given all three samples were not of the expected identity and have not yet been described as new psychoactive substances in the literature, this study presents a full characterisation of each compound. As exemplified by this rapid identification of three unexpected new psychoactive substances, drug checking can be used as an effective method to monitor the unregulated drug market.Drug checking is a herm reduction measure allowing the public to test the content and purity of drugs before consumption that can also serve as an effective way to monitor the unregulated drug market. In June 2023, three samples were presented to the CanTEST Health and Drug Checking Service located in Canberra, Australia. In each case, analysis revealed substances that did not meet client expectation and were instead identified as previously undocumented new psychoactive substances.image
    Original languageEnglish
    Number of pages11
    JournalDrug Testing and Analysis
    DOIs
    Publication statusPublished - 11 Jan 2024

    Fingerprint

    Dive into the research topics of 'Identification of three unexpected new psychoactive substances at an Australian drug checking service'. Together they form a unique fingerprint.

    Cite this